Editorial
Immune checkpoint inhibition in small cell lung cancer: a key to reach an unmet need?
Abstract
Small cell lung cancer (SCLC), accounting for 13–15% of all lung cancers, is strongly correlated with smoking and it is associated with a poor overall survival (OS) (2-year OS rate: 5%), particularly in patients with extensive disease (1,2).
